In a paper published in the May 17, 2024, online issue of Cell, investigators from the Duke Human Vaccine Institute reported that a sequence of three immunizations in the HVTN-133 trial was sufficient for the development of heterologous or broadly neutralizing antibodies (bnAbs) that protected against several strains of HIV. The findings are “a real beachhead,” Barton Haynes told BioWorld. Haynes is the director of the Duke Human Vaccine Institute and the senior author of the paper. Read More
Researchers from Deutsches Krebsforschungszentrum DKFZ and affiliated organizations presented data for the novel inhibitor of DNA methyltransferase (DNMT) and histone methyltransferase G9a (HMT-G9a), CM-272, being developed for the treatment of acute myeloid leukemia (AML). Read More
Cancervax Inc. has announced that its University of California, Los Angeles (UCLA) research team has achieved a critical milestone by creating a process to add any antibody to lipid nanoparticles (LNPs) using click chemistry, for targeting cancer cells. Read More
TFF Pharmaceuticals Inc. has announced it is advancing into preclinical testing multivalent universal influenza vaccine candidates to protect against seasonal and pandemic viruses, in collaboration with Cleveland Clinic. Read More
Investigators at Poseida Therapeutics Inc. developed P-KLKB1-101, a nonviral KLKB1 gene editing therapy, being developed for the treatment of hereditary angioedema (HAE). Read More
Nine Square Therapeutics Inc. has disclosed mucolipin-1 modulators reported to be useful for the treatment of metabolic disease, neurodegeneration, aging, immunological disorders, inflammatory disorders, cardiovascular disorders, lysosomal storage disease and cancer. Read More
The FDA has cleared an IND application for GC-1130A, a treatment for mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) being jointly developed by GC Biopharma Corp. and Novel Pharma Inc. Read More
Shanghai Rulink Biopharma Co. Ltd. has synthesized integrin αvβ1, αvβ6 and/or αvβ8 antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Read More
Chengdu Zeling Biomedical Technology Co. Ltd. has identified poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer. Read More
Pheon Therapeutics Ltd. has completed a $120 million series B financing to fund the development of its pipeline of differentiated antibody-drug conjugates (ADCs) for cancer through clinical proof of concept. Read More
Shanghai Leadingtac Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant) targeting moiety reported to be useful for the treatment of cancer. Read More
Ygion Biomedical GmbH has completed a series A financing round of €15 million (US$ 16.3 million) to support the development of individualized neoantigen-based cancer vaccines. Read More
Lowering intraocular pressure (IOP) is still the only approach for treating glaucoma, in which there is mitochondrial damage in the retinal ganglion cells (RGCs). Activating survival pathways in RGCs was thus hypothesized by Indiana University scientists as a strategy for treating glaucoma independently of IOP modulation. Read More
Light Horse Therapeutics Inc. has described transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer. Read More
